Body Space or Junction – Page 2 – Talk Bio

Actionable Insights Powered by AI

GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?

6 months ago talkbio0Tagged Effectiveness, GLP-1s, Glucagon-Like Peptide 1, Industry, Injectables, Manufacture, Market, Oral cavity, Orals, orforglipron, production

Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s

Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic

6 months ago talkbio0Tagged entera, first, GLP-1/glucagon, OPKO, Oral cavity, Ownership

entera, GLP-1/glucagon, first, Oral cavity, OPKO, Ownership, Entera

Ascletis Advances in Obesity Treatment with Promising Oral GLP-1 Data

7 months ago talkbio0Tagged ASC30, Ascletis, Chinese Language, Glucagon-Like Peptide 1, Obesity, Oral cavity, Pharma, pharmaceutical innovation

Ascletis Pharma, oral GLP-1, obesity treatment, weight loss, ASC30, Chinese biotech, pharmaceutical innovation

Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate

7 months ago talkbio0Tagged ASC30, Ascletis, Clinical Trials, CT-996, Obesity, Oral cavity, Pharma, Pharmaceutical competition, Product containing glucagon-like peptide 1 receptor agonist (product), Roche (company)

Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition

Merck & Co. Enters Oral GLP-1 Market with $2 Billion Hansoh Pharma Deal

9 months ago talkbio0Tagged GLP-1 receptor, Hansoh Pharma, Merck & Co., Obesity, Oral cavity, Partnership, pharmaceutical collaboration

Merck & Co., Hansoh Pharma, GLP-1 receptor agonist, oral obesity treatment, pharmaceutical collaboration, biotech partnership

Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug

9 months ago talkbio0Tagged Benefit, cardiometabolic, Glucagon-Like Peptide 1, Hansoh Pharma, HS-10535, Merck, Obesity, Oral cavity, Weight Loss

Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits

Iterum Therapeutics Secures FDA Approval for Orlynvah, Breaking Two-Decade Drought in New UTI Treatments

11 months ago talkbio0Tagged Approved, Etzadroxil, Iterum, Oral cavity, Orlynvah, Penem, probenecid, Uncomplicated, United States Food and Drug Administration, Urinary tract infection, uUTIs

Iterum Therapeutics, FDA Approval, Orlynvah, Uncomplicated Urinary Tract Infections (uUTIs), Sulopenem Etzadroxil and Probenecid, Oral Penem

Terns Pharmaceuticals’ Oral GLP-1 Drug Demonstrates Promising Weight Loss Results

1 year ago talkbio0Tagged Glucagon-Like Peptide 1, Laridae, Obesity, Oral cavity, TERN-601, Weight Loss

Terns Pharmaceuticals, Oral GLP-1, Weight Loss, Obesity Treatment, TERN-601

Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss in Phase 1 Trial

1 year ago talkbio0Tagged Agonist, Laridae, Obesity, Oral cavity, phase 1 trial, TERN-601, Weight Loss

Terns Pharmaceuticals, TERN-601, Oral GLP-1R Agonist, Phase 1 Trial, Weight Loss, Obesity Treatment

Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

1 year ago talkbio0Tagged Agammaglobulinaemia tyrosine kinase, Chronic Spontaneous Urticaria, Inhibitor, Long-term, Novartis, Oral cavity, Phase 3 Clinical Trials, remibrutinib

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor